What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TOP-N53 solution (IMP) containing 80 µg/ml TOP-N53 is applied topically directly to the digital ulcer of patients with systemic sclerosis. The dose if defined by volume and exposure time of the IMP.”In the company’s words, NCT06954597 on ClinicalTrials.gov
- Tested for
- Digital Ulcers in Systemic Sclerosis
- Main trialPhase 2
- “The main goal of this clinical trial is to learn about how safe the new drug TOP-N53 solution is when it is applied to open wounds on the fingertip (digital ulcers) in people with an uncommon illness that results in hard, thickened areas of skin and additional problems with internal organs and blood vessels (systemic sclerosis). Another goal is to learn if different strengths of TOP-N53 can treat certain aspects of the illness. Men and women between 18 and 69 years of age with this illness may participate in the clinical trial. A parallel treatment with Sildenafil 20 mg is allowed for…”In the company’s words, NCT06954597 on ClinicalTrials.gov
Other drugs for Digital Ulcers in Systemic Sclerosis
- L608Pharmosa Biopharm Inc. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Oct 2026 | Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026